Overview

Safety and Efficacy Study of Interferon to Treat Patients Hospitalized for Influenza

Status:
Unknown status
Trial end date:
2011-11-01
Target enrollment:
0
Participant gender:
All
Summary
A Pilot Study to Evaluate the Safety and Efficacy of interferon-Alfacon1 (INFERGEN) in the treatment of patients hospitalized with Influenza-like illness caused by a novel swine origin Influenza virus and other circulating Influenza Viruses. The use of Interferon-alfacon1 as a co-treatment along with the standard of care antiviral is hypothesized to be safe. Clinical improvement of patients is hypothesized to be quicker.
Phase:
Phase 1/Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
University Health Network, Toronto
Treatments:
Interferon alfacon-1
Interferons
Criteria
Inclusion Criteria:

- Able to provide informed consent

- Aged >=18 and < 70

- Hospitalized

- suspect, probable, confirmed influenza A

- symptom onset <8 days

- able to attend all scheduled visits

Exclusion Criteria:

- known hypersensitivity to interferon preparation

- pregnancy

- chronic liver disease

- moderate to severe congestive heart failure, grade III or IV left ventricular function

- previous history of serious psychiatric illness

- history of severe or active autoimmune disease